Compare Cronos Group Inc (CRON) vs Manulife Financial Corporation (MFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs Manulife Financial Corporation — how do they compare? Cronos Group Inc trades at $3.23 (market cap $1.20B), while Manulife Financial Corporation trades at $43.58 (market cap $69.26B). The key difference: Manulife Financial Corporation is far larger — about 57.7× Cronos Group Inc's market cap, and Manulife Financial Corporation pays a 3.27% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cronos Group Inc for 22 Days and Manulife Financial Corporation for 119 Days on average.
| CRON | MFC | |
|---|---|---|
Market Cap | $1.20B | $69.26B |
Volume | 450,387 | 1,347,387 |
Sector | Health | Financials |
52-Week High | $3.55 | $44.77 |
52-Week Low | $2.30 | $31.64 |
Typical Hold Time | 22 Days | 119 Days |
Enterprise Value | $401.73M | $64.51B |
Dividend Yield | — | 3.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.22, down 1.98% on the day, amid a bearish technical signal. The company reported mixed quarterly earnings but achieved record revenue and gross profit in Q2 2026, with net income turning positive. Recent investor day highlighted international expansion and cash flow focus. Valuation ratios show a P/E of 17.11 and P/S of 6.91, with strong net income margin of 39.08% projected for 2026.
Outlook is cautiously optimistic, driven by revenue growth and profitability improvements, but risks include cash flow volatility and competitive pressures. Analyst consensus is mixed with 60% hold rating. The stock's near-term performance hinges on execution of expansion plans and sustained earnings momentum.
Manulife Financial (MFC) trades at $42.12, down 1.89% today, with a bearish technical outlook despite strong fundamentals. The company reported solid Q2 2026 earnings of $0.79 per share, beating expectations, with revenue growth to $53.01 billion in 2025 and improving cash flow trends. Recent institutional investments from Bank of America and others highlight confidence, while analyst consensus remains positive with 57% buy ratings.
MFC presents a mixed outlook: strong operational performance and dividend yield support upside, but technical indicators signal near-term pressure. Key risks include debt levels and market volatility, while opportunities lie in Asia growth and reinsurance deals. The stock trades above the consensus price target of $34.24, suggesting cautious optimism with execution-dependent returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →
